

Kelly-Anne Phillips, Mbbs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2621943/publications.pdf>

Version: 2024-02-01

145
papers

11,048
citations

50276

46
h-index

33894

99
g-index

148
all docs

148
docs citations

148
times ranked

13318
citing authors

#	ARTICLE	IF	CITATIONS
1	Risks of Breast, Ovarian, and Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2402.	7.4	1,898
2	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017, 551, 92-94.	27.8	1,099
3	Cognitive Function in Breast Cancer Patients Receiving Adjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2000, 18, 2695-2701.	1.6	511
4	Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy. <i>New England Journal of Medicine</i> , 2015, 372, 923-932.	27.0	452
5	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1347.	7.4	390
6	Key steps for effective breast cancer prevention. <i>Nature Reviews Cancer</i> , 2020, 20, 417-436.	28.4	386
7	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
8	Obesity and Outcomes in Premenopausal and Postmenopausal Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1686-1691.	2.5	290
9	The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: A meta-analysis of the current literature. <i>Brain and Cognition</i> , 2005, 59, 60-70.	1.8	269
10	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	21.4	265
11	The Y Deletion <i>gr/gr</i> and Susceptibility to Testicular Germ Cell Tumor. <i>American Journal of Human Genetics</i> , 2005, 77, 1034-1043.	6.2	197
12	Local therapy in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 389-398.	2.5	170
13	<i>CHEK2</i> *1100delC Heterozygosity in Women With Breast Cancer Associated With Early Death, Breast Cancer-Specific Death, and Increased Risk of a Second Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 4308-4316.	1.6	162
14	Tamoxifen and Risk of Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Journal of Clinical Oncology</i> , 2013, 31, 3091-3099.	1.6	148
15	Making hard choices easier: a prospective, multicentre study to assess the efficacy of a fertility-related decision aid in young women with early-stage breast cancer. <i>British Journal of Cancer</i> , 2012, 106, 1053-1061.	6.4	144
16	Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. <i>Human Molecular Genetics</i> , 2006, 15, 443-451.	2.9	138
17	Analysis of cancer risk and <i>BRCA1</i> and <i>BRCA2</i> mutation prevalence in the kConFab familial breast cancer resource. <i>Breast Cancer Research</i> , 2006, 8, R12.	5.0	135
18	Breast Cancer Prognosis in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: An International Prospective Breast Cancer Family Registry Population-Based Cohort Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 19-26.	1.6	134

#	ARTICLE	IF	CITATIONS
19	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. <i>Nature Genetics</i> , 2016, 48, 374-386.	21.4	125
20	Adjuvant Breast Cancer Treatment and Cognitive Function: Current Knowledge and Research Directions. <i>Journal of the National Cancer Institute</i> , 2003, 95, 190-197.	6.3	122
21	10-year performance of four models of breast cancer risk: a validation study. <i>Lancet Oncology</i> , The, 2019, 20, 504-517.	10.7	116
22	Agreement Between Self-Reported Breast Cancer Treatment and Medical Records in a Population-Based Breast Cancer Family Registry. <i>Journal of Clinical Oncology</i> , 2005, 23, 4679-4686.	1.6	99
23	Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials. <i>Clinical Cancer Research</i> , 2017, 23, 3628-3637.	7.0	99
24	Putting the Risk of Breast Cancer in Perspective. <i>New England Journal of Medicine</i> , 1999, 340, 141-144.	27.0	98
25	Breast Cancer Risk Prediction Using Clinical Models and 77 Independent Risk-Associated SNPs for Women Aged Under 50 Years: Australian Breast Cancer Family Registry. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 359-365.	2.5	96
26	Breast Carcinomas Arising in Carriers of Mutations in BRCA1 or BRCA2: Are They Prognostically Different?. <i>Journal of Clinical Oncology</i> , 1999, 17, 3653-3663.	1.6	92
27	Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations. <i>Human Reproduction</i> , 2016, 31, 1126-1132.	0.9	84
28	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	2.4	82
29	The role of genetic breast cancer susceptibility variants as prognostic factors. <i>Human Molecular Genetics</i> , 2012, 21, 3926-3939.	2.9	80
30	Prognosis of Breast Cancer in Carriers of BRCA1 and BRCA2 Mutations. <i>New England Journal of Medicine</i> , 2007, 357, 1555-1556.	27.0	79
31	Psychosocial Factors and Survival of Young Women With Breast Cancer: A Population-Based Prospective Cohort Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 4666-4671.	1.6	77
32	Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. <i>Journal of the National Cancer Institute</i> , 2019, 111, 210-213.	6.3	70
33	Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. <i>Breast</i> , 2010, 19, 388-395.	2.2	69
34	Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study. <i>Clinical Genetics</i> , 2006, 70, 198-206.	2.0	67
35	Prognosis of Premenopausal Breast Cancer and Childbirth Prior to Diagnosis. <i>Journal of Clinical Oncology</i> , 2004, 22, 699-705.	1.6	63
36	HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry. <i>Cancer</i> , 2002, 95, 2068-2075.	4.1	61

#	ARTICLE	IF	CITATIONS
37	Risk of Dementia in Older Breast Cancer Survivors: A Population-Based Cohort Study of the Association with Adjuvant Chemotherapy. <i>Journal of the American Geriatrics Society</i> , 2009, 57, 403-411.	2.6	61
38	What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?. <i>Lancet Oncology</i> , The, 2005, 6, 581-588.	10.7	59
39	Identification of Novel Genetic Markers of Breast Cancer Survival. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	56
40	Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 221-226.	2.5	55
41	Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab. <i>Genetics in Medicine</i> , 2017, 19, 30-35.	2.4	53
42	Prevalence of self-reported arm morbidity following treatment for breast cancer in the Australian Breast Cancer Family Study. <i>Breast</i> , 2001, 10, 515-522.	2.2	52
43	Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis. <i>BMC Medicine</i> , 2015, 13, 156.	5.5	51
44	Past recreational physical activity, body size, and all-cause mortality following breast cancer diagnosis: results from the breast cancer family registry. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 531-542.	2.5	50
45	Cohort Profile: The Breast Cancer Prospective Family Study Cohort (ProF-SC). <i>International Journal of Epidemiology</i> , 2016, 45, 683-692.	1.9	48
46	Contralateral prophylactic mastectomy (CPM): A systematic review of patient reported factors and psychological predictors influencing choice and satisfaction. <i>Breast</i> , 2016, 28, 107-120.	2.2	48
47	Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort. <i>Familial Cancer</i> , 2005, 4, 105-113.	1.9	47
48	Predictors of breast cancer screening behavior in women with a strong family history of the disease. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 509-519.	2.5	46
49	Body mass index and breast cancer survival: a Mendelian randomization analysis. <i>International Journal of Epidemiology</i> , 2017, 46, 1814-1822.	1.9	45
50	Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre. <i>British Journal of Cancer</i> , 2013, 109, 1296-1301.	6.4	44
51	Assessing and managing breast cancer risk: Clinicians' current practice and future needs. <i>Breast</i> , 2014, 23, 644-650.	2.2	44
52	Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study. <i>Breast Cancer Research</i> , 2019, 21, 52.	5.0	44
53	Risk-reducing surgery in women with familial susceptibility for breast and/or ovarian cancer. <i>European Journal of Cancer</i> , 2006, 42, 621-628.	2.8	43
54	Perceptions of Ashkenazi Jewish breast cancer patients on genetic testing for mutations in BRCA1 and BRCA2. <i>Clinical Genetics</i> , 2000, 57, 376-383.	2.0	42

#	ARTICLE	IF	CITATIONS
55	The International Testicular Cancer Linkage Consortium: A clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 492-499.	1.6	42
56	Do <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers Have Earlier Natural Menopause Than Their Noncarrier Relatives? Results From the Kathleen Cuninghame Foundation Consortium for Research Into Familial Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3920-3925.	1.6	42
57	Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Breast Cancer Research</i> , 2020, 22, 8.	5.0	41
58	Average age-specific cumulative risk of breast cancer according to type and site of germline mutations in <i>BRCA1</i> and <i>BRCA2</i> estimated from multiple-case breast cancer families attending Australian family cancer clinics. <i>Human Genetics</i> , 2003, 112, 542-551.	3.8	40
59	Morphological predictors of <i>BRCA1</i> germline mutations in young women with breast cancer. <i>British Journal of Cancer</i> , 2011, 104, 903-909.	6.4	40
60	Preventing breast and ovarian cancers in high-risk <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Medical Journal of Australia</i> , 2013, 199, 680-683.	1.7	39
61	Screening behavior in women at increased familial risk for breast cancer. <i>Familial Cancer</i> , 2006, 5, 359-368.	1.9	38
62	Adjuvant ovarian function suppression and cognitive function in women with breast cancer. <i>British Journal of Cancer</i> , 2016, 114, 956-964.	6.4	38
63	Analysis of the <i>DND1</i> gene in men with sporadic and familial testicular germ cell tumors. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 247-252.	2.8	37
64	Recreational Physical Activity Is Associated with Reduced Breast Cancer Risk in Adult Women at High Risk for Breast Cancer: A Cohort Study of Women Selected for Familial and Genetic Risk. <i>Cancer Research</i> , 2020, 80, 116-125.	0.9	37
65	The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation. <i>Human Reproduction</i> , 2020, 35, 1864-1874.	0.9	36
66	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in <i>BRCA1/2</i> Mutation Carriers. <i>PLoS ONE</i> , 2015, 10, e0120020.	2.5	34
67	Oral contraceptive use and ovarian cancer risk for <i>BRCA1/2</i> mutation carriers: an international cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 51.e1-51.e17.	1.3	34
68	Using SNP genotypes to improve the discrimination of a simple breast cancer risk prediction model. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 887-896.	2.5	33
69	iPrevent [®] : a tailored, web-based, decision support tool for breast cancer risk assessment and management. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 171-182.	2.5	33
70	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a <i>BRCA1</i> and <i>BRCA2</i> Mutation Carrier Cohort Study. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky023.	2.9	33
71	Prediagnosis Reproductive Factors and All-Cause Mortality for Women with Breast Cancer in the Breast Cancer Family Registry. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1792-1797.	2.5	32
72	Transcriptome-wide association study of breast cancer risk by estrogen receptor status. <i>Genetic Epidemiology</i> , 2020, 44, 442-468.	1.3	32

#	ARTICLE	IF	CITATIONS
73	A Randomized Controlled Trial of a Decision Aid for Women at Increased Risk of Ovarian Cancer. <i>Medical Decision Making</i> , 2006, 26, 360-372.	2.4	31
74	Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuninghame Foundation Consortium for Research into Familial Breast Cancer (kConFab). <i>Breast Cancer Research and Treatment</i> , 2010, 120, 715-723.	2.5	29
75	Alcohol consumption, cigarette smoking, and familial breast cancer risk: findings from the Prospective Family Study Cohort (ProF-SC). <i>Breast Cancer Research</i> , 2019, 21, 128.	5.0	27
76	Common germline polymorphisms associated with breast cancer-specific survival. <i>Breast Cancer Research</i> , 2015, 17, 58.	5.0	26
77	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 368-378.	2.5	24
78	A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2004, 93, 417-421.	1.4	23
79	Younger age-at-diagnosis for familial malignant testicular germ cell tumor. <i>Familial Cancer</i> , 2009, 8, 451-456.	1.9	21
80	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. <i>Cancer Causes and Control</i> , 2016, 27, 679-693.	1.8	21
81	Women's preferences for contralateral prophylactic mastectomy: An investigation using protection motivation theory. <i>Patient Education and Counseling</i> , 2016, 99, 814-822.	2.2	21
82	Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the Breast Cancer Family Registry. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 167-176.	2.5	20
83	Women's preferences for selective estrogen reuptake modulators: An investigation using protection motivation theory. <i>Patient Education and Counseling</i> , 2014, 96, 106-112.	2.2	20
84	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. <i>Breast Cancer Research</i> , 2015, 17, 18.	5.0	20
85	Debated Role of Ovarian Protection With Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Women With Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 804-805.	1.6	20
86	Clinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy. <i>Clinical Genetics</i> , 2003, 64, 111-121.	2.0	19
87	Cancer Risk Management Practices of Noncarriers Within BRCA1/2 Mutation-Positive Families in the Kathleen Cuninghame Foundation Consortium for Research Into Familial Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 225-232.	1.6	19
88	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. <i>Nature Communications</i> , 2021, 12, 1078.	12.8	19
89	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	1.4	18
90	Preventing ovarian failure associated with chemotherapy. <i>Medical Journal of Australia</i> , 2018, 209, 412-416.	1.7	18

#	ARTICLE	IF	CITATIONS
91	Australian clinicians and chemoprevention for women at high familial risk for breast cancer. <i>Hereditary Cancer in Clinical Practice</i> , 2009, 7, 9.	1.5	17
92	Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 1057-1061.	2.5	17
93	2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. <i>Nature Communications</i> , 2014, 5, 4051.	12.8	16
94	Transitioning to routine breast cancer risk assessment and management in primary care: what can we learn from cardiovascular disease?. <i>Australian Journal of Primary Health</i> , 2016, 22, 255.	0.9	16
95	Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen?. <i>Future Oncology</i> , 2014, 10, 499-502.	2.4	15
96	Clinical management of women at high risk of breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2015, 27, 6-13.	2.0	13
97	Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ. <i>British Journal of Cancer</i> , 2018, 119, 36-39.	6.4	13
98	Comparing 5-Year and Lifetime Risks of Breast Cancer Using the Prospective Family Study Cohort. <i>Journal of the National Cancer Institute</i> , 2021, 113, 785-791.	6.3	13
99	Current perspectives on BRCA1- and BRCA2-associated breast cancers. <i>Internal Medicine Journal</i> , 2001, 31, 349-356.	0.8	12
100	Does stress increase risk of breast cancer? A 15-year prospective study. <i>Psycho-Oncology</i> , 2018, 27, 1908-1914.	2.3	12
101	Survival from breast cancer in women with a BRCA2 mutation by treatment. <i>British Journal of Cancer</i> , 2021, 124, 1524-1532.	6.4	12
102	Chemotherapy for soft tissue sarcomas. <i>Acta Orthopaedica</i> , 1997, 68, 133-138.	1.4	11
103	Women's preferences for contralateral prophylactic mastectomy following unilateral breast cancer: What risk-reduction makes it worthwhile?. <i>Breast</i> , 2017, 31, 233-240.	2.2	11
104	Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199). <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz075.	2.9	11
105	Assessment of Ovarian Function in Phase III (Neo)Adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation. <i>Journal of the National Cancer Institute</i> , 2021, , .	6.3	11
106	Psychosocial factors and uptake of risk-reducing salpingo-oophorectomy in women at high risk for ovarian cancer. <i>Familial Cancer</i> , 2013, 12, 101-109.	1.9	10
107	Predicting women's intentions for contralateral prophylactic mastectomy: An application of an extended theory of planned behaviour. <i>European Journal of Oncology Nursing</i> , 2016, 21, 57-65.	2.1	10
108	Conservative management of reproductive cancers. Ovarian protection during treatment. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2019, 55, 49-58.	2.8	10

#	ARTICLE	IF	CITATIONS
109	The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing. <i>JMIR Formative Research</i> , 2018, 2, e24.	1.4	10
110	Breast carcinoma in carriers of BRCA1 or BRCA2 mutations. <i>Cancer</i> , 1998, 83, 2251-2254.	4.1	9
111	Genetic testing in women with breast cancer: implications for treatment. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 991-1002.	2.4	9
112	Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort. <i>International Journal of Cancer</i> , 2019, 145, 370-379.	5.1	9
113	Accuracy of Risk Estimates from the iPrevent Breast Cancer Risk Assessment and Management Tool. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz066.	2.9	8
114	Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study. <i>Gynecologic Oncology</i> , 2020, 156, 131-139.	1.4	8
115	Bilateral Salpingo-oophorectomy and Breast Cancer Risk for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Assessing the Evidence. <i>Cancer Prevention Research</i> , 2021, 14, 983-994.	1.5	8
116	Oral Contraceptive Use in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Absolute Cancer Risks and Benefits. <i>Journal of the National Cancer Institute</i> , 2022, 114, 540-552.	6.3	7
117	Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer. <i>Familial Cancer</i> , 2011, 10, 505-514.	1.9	6
118	Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians. <i>Cancer Prevention Research</i> , 2021, 14, 131-144.	1.5	6
119	Loss of Heterozygosity Analysis in Ductal Lavage Samples from BRCA1 and BRCA2 Carriers: A Cautionary Tale. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1396-1398.	2.5	5
120	Socioeconomic status and survival from breast cancer for young, Australian, urban women. <i>Australian and New Zealand Journal of Public Health</i> , 2010, 34, 200-205.	1.8	5
121	Misperceptions of ovarian cancer risk in women at increased risk for hereditary ovarian cancer. <i>Familial Cancer</i> , 2014, 13, 153-162.	1.9	5
122	Testing for Gene-Environment Interactions Using a Prospective Family Cohort Design: Body Mass Index in Early and Later Adulthood and Risk of Breast Cancer. <i>American Journal of Epidemiology</i> , 2017, 185, 487-500.	3.4	5
123	Medication to prevent breast cancer "too much to swallow?". <i>Medical Journal of Australia</i> , 2011, 195, 646-649.	1.7	4
124	The value of clinical breast examination in a breast cancer surveillance program for women with germline <i>BRCA1</i> or <i>BRCA2</i> mutations. <i>Medical Journal of Australia</i> , 2021, 215, 460-464.	1.7	4
125	Motivators of Inappropriate Ovarian Cancer Screening: A Survey of Women and Their Clinicians. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa110.	2.9	4
126	Weight is More Informative than Body Mass Index for Predicting Postmenopausal Breast Cancer Risk: Prospective Family Study Cohort (ProF-SC). <i>Cancer Prevention Research</i> , 2022, 15, 185-191.	1.5	4

#	ARTICLE	IF	CITATIONS
127	An Online Educational Facility for Medical Oncology Trainees: www.vmotg.org. Journal of Clinical Oncology, 2001, 19, 2566-2569.	1.6	3
128	Prostate screening uptake in Australian BRCA1 and BRCA2 carriers. Hereditary Cancer in Clinical Practice, 2007, 5, 161.	1.5	3
129	Women's preferences for selective estrogen reuptake modulators: an investigation using the time trade-off technique. SpringerPlus, 2014, 3, 264.	1.2	3
130	Screening and Diagnosis of Ovarian Cancer – High Risk. , 2004, , 341-354.		2
131	Abstract P1-12-06: Co-SOFT: The cognitive function substudy of the suppression of ovarian function trial (SOFT). , 2015, , .		2
132	Development of a tailored, computerized, breast cancer risk assessment and decision support tool: What do clinicians want?. Journal of Clinical Oncology, 2013, 31, e20660-e20660.	1.6	2
133	Management of Women at High Familial Risk of Breast and Ovarian Cancer. , 2009, , 941-967.		2
134	Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials. Breast, 2022, , .	2.2	2
135	Bilateral Salpingo-Oophorectomy to Reduce Breast Cancer Risk in Women With Germline BRCA1 or BRCA2 Pathogenic Variants – Caution Needed. JAMA Oncology, 2021, 7, 1401.	7.1	1
136	Underutilisation of breast cancer prevention medication in Australia. Breast, 2021, 60, 35-37.	2.2	1
137	Assessing breast cancer risk in primary care: What can we learn from cardiovascular disease?. Journal of Clinical Oncology, 2013, 31, 17-17.	1.6	1
138	Assessment of ovarian function as an endpoint in breast cancer clinical trials: A systematic review.. Journal of Clinical Oncology, 2020, 38, e14098-e14098.	1.6	1
139	Abortion and breast cancer risk for Australian women. Medical Journal of Australia, 2014, 201, 381-381.	1.7	1
140	Pregnancy induced hyperplasia of residual breast tissue following risk reducing contralateral mastectomy - simply interesting or a clinically important observation. Cancer Treatment and Research Communications, 2022, 30, 100504.	1.7	1
141	Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk. JNCI Cancer Spectrum, 2021, 5, pkab090.	2.9	1
142	Maximizing the Clinical Benefit of DPYD Genotyping: Extending the Opportunity of Personalized Management to Family Members Through Cascade Testing. JCO Precision Oncology, 2018, 2, 1-5.	3.0	0
143	Unexpected diagnosis of spinal leptomeningeal metastatic disease on MRI myelography. Journal of Clinical Neuroscience, 2019, 66, 259-261.	1.5	0
144	Abstract P5-19-03: What are the barriers to assessment of ovarian toxicity in breast cancer clinical trials?. Cancer Research, 2022, 82, P5-19-03-P5-19-03.	0.9	0

#	ARTICLE	IF	CITATIONS
145	Risk of Peritoneal Cancer After Risk-Reducing Bilateral Salpingo-Oophorectomy for Women With Germline <i>BRCA</i> Pathogenic Variants: A Cause for Concern or Potentially Avoidable?. Journal of Clinical Oncology, 2022, , JCO2200325.	1.6	0